Ghana ap­proves Ox­ford Uni­ver­si­ty's malar­ia vac­cine for chil­dren

The R21/Ma­trix-M malar­ia vac­cine has scored its first reg­u­la­to­ry clear­ance world­wide with an ap­proval by FDA Ghana, Ox­ford Uni­ver­si­ty an­nounced to­day. Its man­u­fac­tur­ing part­ner could make 200 mil­lion dos­es an­nu­al­ly.

The vac­cine is ap­proved in chil­dren 5 to 36 months old, the age group at the high­est risk of death from malar­ia. The Uni­ver­si­ty of Ox­ford de­vel­oped the vac­cine with No­vavax’s ad­ju­vant tech­nol­o­gy, while the Serum In­sti­tute of In­dia PvT (SI­IPL) man­u­fac­tured and scaled up the pro­duc­tion of the jab. SI­IPL is the man­u­fac­tur­ing and com­mer­cial­iza­tion li­cense hold­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.